India's National Pharmaceutical Pricing Authority has announced newprices for 49 formulations based on changes in the prices of related bulk drugs.
It has raised the ceiling prices of 19 formulations from 4% to 13%, reduced the prices of 26 formulations in a range from 3% to over 70% and, for the first time, announced new prices for four vitamin combinations.
The new prices have been fixed under the Drug Prices Control Order, which fixes the prices of both bulk drugs and formulations produced and marketed in India.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze